We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Enzyme-Loaded Magnetic Nanoparticles Suitable for Therapeutic and Industrial Applications

By LabMedica International staff writers
Posted on 25 Apr 2016
Members of a novel class of nano-sized transport vessels are composed of only two biocompatible components: an enzyme and magnetite nanoparticles.

Magnetically controlled enzymatic nanoparticles have received much attention for both therapeutic and industrial applications. More...
Such materials usually comprise at least four components: the enzyme, magnetic nanoparticles, stabilizing components, and an organic or inorganic (or hybrid) matrix as a carrier. However, such combinations can affect the magnetic response and/or the enzymatic activity, and also face regulatory restrictions that prevent them from being used for intravenous administration.

To overcome these difficulties, investigators at ITMO University (St. Petersburg, Russia) and their colleagues at the Hebrew University of Jerusalem (Israel), and Cyril and Methodius University (Skopje, Macedonia) developed a new class of magnetically controlled nanoparticles made from enzymes that have been entrapped directly within magnetite particles.

These particles were made by adding enzymes directly to a magnetite hydrosol mixture. Magnetite particles surrounded the enzymes, and after drying, formed a firm porous structure from which the enzyme could not escape.

The investigators reported in the March 16, 2016, online edition of the journal Chemistry of Materials that they had used the direct entrapment approach to create a series of magnetic biocomposites with enzymes of therapeutic and industrial interest including carbonic anhydrase, ovalbumin, horseradish peroxidase, acid phosphatase, proteinase, and xylanase.

The activity of the entrapped enzymes was studied at different temperatures and concentrations, and it was found that they showed remarkable thermal stabilization induced by the magnetite matrix. For example, entrapped carbonic anhydrase catalyzed the decomposition of p-nitrophenylacetate at a temperature of 90 degrees Celsius, while the free enzyme completely lost activity and denaturized at 70 degrees Celsius.

"The nanocomposite is absolutely biocompatible and harmless for injection into the human body," said Dr. Andrey Drozdov, a research associate in the international laboratory of solution chemistry of advanced materials and technologies at ITMO University. "Separately, both magnetite and therapeutic enzymes have medical approval for intravenous injection. Therefore, to approve their joint use should not be difficult. The body already knows what to do with these substances and how to incorporate them into the process of metabolism. Using a magnetic field, the particles can be condensed on blood clots; moreover, such systems will work for quite a long time until the enzyme is completely oxidized."

Related Links:
ITMO University
Hebrew University of Jerusalem
Cyril and Methodius University

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Immunofluorescence Analyzer
IFA System
New
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.